Advertisement

Journal of Neuro-Oncology

, Volume 101, Issue 2, pp 257–265 | Cite as

Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors

  • Soley Bayraktar
  • Ulas D. Bayraktar
  • Juan C. Ramos
  • Alexandra Stefanovic
  • Izidore S. Lossos
Clinical Study – Patient Study

Abstract

Primary central nervous system lymphoma (PCNSL) accounts for approximately 4% of all primary brain tumors and has a poor prognosis in both immunocompetent as well as in immunocompromised patients. We conducted a retrospective analysis to examine the clinical characteristics and prognostic factors in HIV-negative and HIV-positive patients with PCNSL and to assess the effect of highly active antiretroviral therapy (HAART) therapy on the outcome of HIV-positive patients. Patients diagnosed with PCNSL between 1999 and 2008 at our institution were divided into two groups based on their HIV status. Their demographic and clinical characteristics were compared using the chi-square test. Kaplan–Meier survival curves were constructed employing the univariate log-rank test. Multivariate analyses of survival were performed by Cox proportional hazards models incorporating the prognostic factors identified in the univariate log rank test. Forty-one HIV-positive patients and 45 HIV-negative patients were identified. HIV-positive patients were younger, more likely to present with seizures and elevated serum LDH levels. There were significant differences in complete remission (CR) rates (P = 0.010) and overall survival (OS) (P = 0.034) in favor of the HIV-negative group. In the HIV-positive group, OS was better in patients with KPS > 70 and patients who received HAART, but remained inferior to that in the HIV-negative patients. HIV-positive patients had a worse prognosis compared to HIV-negative patients despite similar clinical characteristics. Better performance status (KPS > 70) and treatment with HAART conferred better OS in HIV-positive patients.

Keywords

Primary CNS lymphoma HIV Prognostic factors EBV AZT 

Notes

Acknowledgment

ISL is supported by the United States Public Health Service, National Institutes of Health [grant numbers R01-CA109335, R01-CA122105], Fidelity Foundation and the Dwoskin Family Foundation.

References

  1. 1.
    Lister A, Abrey LE, Sandlund JT (2002) Central nervous system lymphoma. Hematol Am Soc Hematol Educ Program 2002:283–296Google Scholar
  2. 2.
    Olson JE, Janney CA, Rao RD et al (2002) The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 95:1504–1510CrossRefPubMedGoogle Scholar
  3. 3.
    Rosenblum ML, Levy RM, Bredesen DE et al (1988) Primary central nervous system lymphomas in patients with AIDS. Ann Neurol 23(Suppl):S13–S16CrossRefPubMedGoogle Scholar
  4. 4.
    Welch K, Finkbeiner W, Alpers CE et al (1984) Autopsy findings in the acquired immune deficiency syndrome. JAMA 252:1152–1159CrossRefPubMedGoogle Scholar
  5. 5.
    Sparano JA, Anand K, Desai J et al (1999) Effect of highly active antiretroviral therapy on the incidence of HIV-associated malignancies at an urban medical center. J Acquir Immune Defic Syndr 21(Suppl 1):S18–S22PubMedGoogle Scholar
  6. 6.
    Inungu J, Melendez MF, Montgomery JP (2002) AIDS-related primary brain lymphoma in Michigan, January 1990 to December 2000. AIDS Patient Care STDS 16:107–112CrossRefPubMedGoogle Scholar
  7. 7.
    Panageas KS, Elkin EB, DeAngelis LM et al (2005) Trends in survival from primary central nervous system lymphoma, 1975–1999: a population-based analysis. Cancer 104:2466–2472CrossRefPubMedGoogle Scholar
  8. 8.
    Mounier N, Spina M, Gisselbrecht C (2007) Modern management of non-Hodgkin lymphoma in HIV-infected patients. Br J Haematol 136:685–698CrossRefPubMedGoogle Scholar
  9. 9.
    Bessell EM, Lopez-Guillermo A, Villa S et al (2002) Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol 20:231–236CrossRefPubMedGoogle Scholar
  10. 10.
    LMSW DeAngelis, Seiferheld W, Schold SC (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20:4643–4648CrossRefGoogle Scholar
  11. 11.
    Gavrilovic IT, Hormigo A, Yahalom J et al (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24:4570–4574CrossRefPubMedGoogle Scholar
  12. 12.
    O’Brien PC, Roos DE, Pratt G et al (2006) Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys 64:408–413CrossRefPubMedGoogle Scholar
  13. 13.
    Yamanaka R, Shinbo Y, Sano M et al (2007) Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. Leuk Lymphoma 48:1119–1126CrossRefPubMedGoogle Scholar
  14. 14.
    Freilich RJDJ, Delattre J-Y, Monjour A, DeAngelis LM (1996) Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology 46:435–439PubMedGoogle Scholar
  15. 15.
    Glass J, Gruber ML, Cher L et al (1994) Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 81:188–195CrossRefPubMedGoogle Scholar
  16. 16.
    Tanner JE, Alfieri C (2001) The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transpl Infect Dis 3:60–69CrossRefPubMedGoogle Scholar
  17. 17.
    Raez L, Cabral L, Cai JP et al (1999) Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retrovir 15:713–719CrossRefPubMedGoogle Scholar
  18. 18.
    Schwaighofer BW, Hesselink JR, Press GA et al (1989) Primary intracranial CNS lymphoma: MR manifestations. AJNR Am J Neuroradiol 10:725–729PubMedGoogle Scholar
  19. 19.
    Gage JT, Vance EA, Hildenbrand PG et al (2000) Brain lesion and AIDS. Proc (Bayl Univ Med Cent) 13:424–429Google Scholar
  20. 20.
    Antinori A, Ammassari A, Luzzati R et al (2000) Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Gruppo Italiano Cooperativo AIDS and Tumori. Neurology 54:993–997PubMedGoogle Scholar
  21. 21.
    Antinori A, Ammassari A, De Luca A et al (1997) Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology 48:687–694PubMedGoogle Scholar
  22. 22.
    Fitzsimmons A, Upchurch K, Batchelor T (2005) Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin N Am 19:689–703, viiGoogle Scholar
  23. 23.
    De Luca A, Antinori A, Cingolani A (1995) Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma. Br J Hematol 90:844–849CrossRefGoogle Scholar
  24. 24.
    Antinori A, De Rossi G, Ammassari A et al (1999) Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol 17:554–560PubMedGoogle Scholar
  25. 25.
    Abrey LE, Batchelor TT, Ferreri AJ et al (2005) Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034–5043CrossRefPubMedGoogle Scholar
  26. 26.
    DeAngelis LM (1999) Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neurooncol 43:249–257CrossRefPubMedGoogle Scholar
  27. 27.
    Roychowdhury S, Peng R, Baiocchi RA et al (2003) Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res 63:965–971PubMedGoogle Scholar
  28. 28.
    Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711–5715CrossRefPubMedGoogle Scholar
  29. 29.
    Corti M, Villafane F, Trione N et al (2004) Primary central nervous system lymphomas in AIDS patients. Enferm Infecc Microbiol Clin 22:332–336CrossRefPubMedGoogle Scholar
  30. 30.
    Raez LE, Patel P, Feun L et al (1998) Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog 9:199–208PubMedGoogle Scholar
  31. 31.
    Gabbai AA, Hochberg FH, Linggood RM et al (1989) High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J Neurosurg 70:190–194CrossRefPubMedGoogle Scholar
  32. 32.
    Littman P, Wang CC (1975) Reticulum cell sarcoma of the brain. A review of the literature and a study of 19 cases. Cancer 35:1412–1420CrossRefPubMedGoogle Scholar
  33. 33.
    Dahlborg SA, Henner WD, Crossen JR et al (1996) Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2:166–174PubMedGoogle Scholar
  34. 34.
    Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18:3144–3150PubMedGoogle Scholar
  35. 35.
    Jacomet C, Girard PM, Lebrette MG et al (1997) Intravenous methotrexate for primary central nervous system non-Hodgkin’s lymphoma in AIDS. AIDS 11:1725–1730CrossRefPubMedGoogle Scholar
  36. 36.
    Khoo VS, Liew KH (1999) Acquired immunodeficiency syndrome-related primary cerebral lymphoma. Clin Oncol (R Coll Radiol) 11:6–14Google Scholar
  37. 37.
    Aboulafia DM (2002) Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clin Infect Dis 34:1660–1662CrossRefPubMedGoogle Scholar
  38. 38.
    Gasser O, Bihl FK, Wolbers M et al (2007) HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med 4:e96CrossRefPubMedGoogle Scholar
  39. 39.
    Nelson DF, Martz KL, Bonner H et al (1992) Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9–17CrossRefPubMedGoogle Scholar
  40. 40.
    Hoffmann C, Tabrizian S, Wolf E et al (2001) Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS 15:2119–2127CrossRefPubMedGoogle Scholar
  41. 41.
    Skiest DJ (2003) Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS 17:1787–1793CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Soley Bayraktar
    • 1
  • Ulas D. Bayraktar
    • 1
  • Juan C. Ramos
    • 1
  • Alexandra Stefanovic
    • 1
  • Izidore S. Lossos
    • 1
    • 2
  1. 1.Division of Hematology and Oncology, Department of MedicineUniversity of Miami, Sylvester Comprehensive Cancer CenterMiamiUSA
  2. 2.Department of Molecular and Cellular Pharmacology, Miller School of MedicineUniversity of MiamiMiamiUSA

Personalised recommendations